5
Rekvina Labs
REKVINALABORATORIESLTD NSE
Rekvina Labs
HealthcareNSE: REKVINALABORATORIESLTD BSE: 526075 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹64.70 Cr
Volatility
High Risk
P/E Ratio
-187.9
EBITDA
₹-0.30 Cr
Return on Equity
20.74%
Debt to Equity
0
Book Value
₹3.47
52W High
₹58.24
52W Low
₹6.75
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Promoter holding has increased by 35.7% over last quarter.
Weaknesses
2- Company has low interest coverage ratio.
- Company has high debtors of 172 days.
Growth Rate
Revenue Growth
—
Net Income Growth
200%
Cash Flow Change
-211%
ROE
-49.75% lower than
3Y
ROCE
-49.75% lower than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.35 | 0.72 | 0.67 |
| Expenses | 0 | 0.01 | 0 | 0 | 0 | 0.07 | 0.02 | 0.04 | 0.04 | 0.23 | 0.47 | 0.78 | 0.79 |
| Operating Profit | 0 | -0.01 | 0 | 0 | 0 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| OPM % | — | — | — | — | — | — | — | — | — | -15% | -34.29% | -8.33% | -17.91% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | -0.01 | 0 | 0 | 0 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| Tax % | — | 0% | — | — | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0 | -0.01 | 0 | 0 | 0 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| EPS in Rs | 0 | -0.01 | 0 | 0 | 0 | -0.06 | -0.02 | -0.03 | -0.03 | -0.02 | -0.1 | -0.05 | -0.1 |
Profit & Loss
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.08 | 0.03 | 0.06 | 0 | 0 | 0 | 0 | -0.04 | 0 | 0 | 0 | 1.27 | 1.94 |
| Expenses | 0.05 | 0.03 | 0.12 | 0.05 | 0.1 | 0.15 | 0.06 | 0.04 | 0 | 0.02 | 0.14 | 1.52 | 2.27 |
| Operating Profit | 0.03 | 0 | -0.06 | -0.05 | -0.1 | -0.15 | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| OPM % | 37.5% | 0% | -100% | — | — | — | — | — | — | — | — | -19.69% | -17.01% |
| Other Income | 0 | 0 | 0 | 0.03 | 0.02 | 0.15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.03 | 0 | -0.06 | -0.02 | -0.08 | 0 | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| Tax % | 33.33% | — | 0% | 0% | 0% | — | 0% | 0% | — | 0% | 0% | 0% | — |
| Net Profit | 0.02 | 0 | -0.06 | -0.02 | -0.08 | 0 | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| EPS in Rs | 0.02 | 0 | -0.05 | -0.02 | -0.07 | 0 | -0.05 | -0.07 | 0 | -0.02 | -0.12 | -0.21 | -0.27 |
| Div. Payout % | 0% | — | 0% | 0% | 0% | — | 0% | 0% | — | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3 | -3 | -3.21 | -3.35 | -4.24 |
| Borrowings | 0 | 0.01 | 0.01 | 0.17 | 0.21 | 0 | 0 | 0 | 0.08 | 0.04 | 0.25 | 1.47 |
| Other Liabilities | 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.17 | 0.12 | 0.94 |
| Total Liabilities | 0.77 | 0.66 | 0.64 | 0.79 | 0.8 | 0.28 | 0.24 | 0.19 | 0.2 | 0.01 | 0.03 | 1.18 |
| Fixed Assets | 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0 | 0 | 0 |
| Other Assets | 0.45 | 0.46 | 0.44 | 0.59 | 0.6 | 0.08 | 0.04 | -0.01 | 0 | 0.01 | 0.03 | 1.18 |
| Total Assets | 0.77 | 0.66 | 0.64 | 0.79 | 0.8 | 0.28 | 0.24 | 0.19 | 0.2 | 0.01 | 0.03 | 1.18 |
Cash Flow
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| Investing | 0.01 | 0.02 | 0.07 | -0.07 | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | 0 |
| Financing | 0 | 0.01 | 0 | 0.16 | 0.04 | 0 | 0 | 0 | 0 | 0.01 | 0.21 | 0.58 |
| Net Cash Flow | 0 | 0 | 0.03 | 0.1 | 0.01 | -0.01 | -0.01 | 0 | 0.01 | 0 | 0.02 | -0.01 |
| Free Cash Flow | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| CFO/OP | -33 | — | 67 | -20 | 20 | 7 | 17 | 50 | — | 50 | 136 | 236 |
Ratios
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,004 | 3,042 | 1,703 | — | — | — | — | 0 | — | — | — | 172 |
| Inventory Days | — | — | — | — | — | — | — | 0 | — | — | — | 0 |
| Cash Conversion Cycle | 1,004 | 3,042 | 1,703 | — | — | — | — | 0 | — | — | — | 172 |
| Working Capital Days | 1,460 | 4,015 | 1,460 | — | — | — | — | -1,643 | — | — | — | -359 |
| ROCE % | 4.51% | 0% | -11.11% | -3.45% | -12.7% | — | -50% | -160% | 0% | — | — | -333.33% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Rekvina Labs insights
54 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director
12 Sep - Amit Mukesh Shah resigned as Managing Director and Director effective 11 September 2026. 12 Sep - Amit Mukesh Shah resigned as Managing Director and Director effective 11 September 2026.
2
Clarification sought from Rekvina Laboratories Ltd
12 Aug - Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors … 12 Aug - Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors …
3
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 2 Sept 2026
General_Announcements
Frequently Asked Questions about Rekvina Labs
What does Rekvina Labs Ltd do?
[1]Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.[2]
Where is Rekvina Labs Ltd (526075) listed?
Rekvina Labs Ltd trades as REKVINALABORATORIESLTD on the NSE and under code 526075 on the BSE.
Which sector does Rekvina Labs Ltd belong to?
Rekvina Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Rekvina Labs Ltd?
Rekvina Labs Ltd has a market capitalisation of ₹64.7 Cr, which places it in the Small Cap band.
What is the PE ratio of Rekvina Labs Ltd?
Rekvina Labs Ltd trades at a PE ratio of -187.90, against a book value of ₹3.47 per share.
What is the 52-week high and low of Rekvina Labs Ltd?
Over the last 52 weeks Rekvina Labs Ltd has traded between ₹6.75 and ₹58.24.
What is the Return on Equity (ROE) of Rekvina Labs Ltd?
Rekvina Labs Ltd reported a return on equity of 20.74%. Its debt-to-equity ratio is 0.00.
Company Information
[1]Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.[2]
Website rekvinalaboratories.com
Face Value ₹ 5
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526075.md for Rekvina Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.